Asbestos Research | Science Advisory Board | Anna Nowak, MD

This Meso Foundation’s Science Advisory board works to raise continued awareness about the need for mesothelioma and asbestos research. Led by some of the best mesothelioma specialists in the field, the Board serves as a resource for patients and families, helping to offer an outlet for education as well as striving to improve mesothelioma treatment options.

Among those on our board of mesothelioma and asbestos research experts is Dr. Anna Nowak.

Meet Anna Nowak, MD

Mesothelioma and Asbestos Research Experts: Anna Nowak, MD

Prof Anna Nowak is a Medical Oncologist and member of the Perth Mesothelioma Centre and National Research Centre for Asbestos Related Diseases (NCARD) who has participated actively in mesothelioma research over the past 10 years, and has received international recognition in this area. She works closely with other researchers in this field at Sir Charles Gairdner Hospital and UWA. Prof Nowak has been active in pre-clinical research in this disease.

Her laboratory work in mesothelioma research includes a PhD thesis on combination chemo-immunotherapy in a murine model; this work was awarded at local, national, and international level, winning the International Mesothelioma Interest Group New Investigator Award in 2002. She returned to UWA in 2005 to pursue laboratory work and clinical translational work in mesothelioma after a postdoctoral fellowship working in clinical trials research. She has given numerous oral presentations and published abstracts of her work at national and international meetings.

Her clinical research on unidimensional measurement of response in mesothelioma culminated in the development of the Modified RECIST Criteria for tumour response which have been widely accepted for use in clinical trials in this disease. She has been an invited speaker internationally on tumour measurement and clinical trials in mesothelioma. She also performed the first published validation of the use of a quality of life tool in clinical trials in mesothelioma. More recently, she has continued to investigate the role of PET scanning in prognostication and monitoring of treatment response in mesothelioma, and is the principal investigator of an investigator-initiated phase II clinical trial of sunitinib as second line therapy in malignant mesothelioma. Her clinical research work outside of mesothelioma includes active participation in clinical trials, psycho-oncology, and translational research in high grade glioma.


Believe in a Cure!

Contact us here for immediate expert help and a free copy of the book "100 Questions & Answers About Mesothelioma."

(877) END-MESO
(877) 363-6376